For the quarter ending 2026-03-31, APGE had $320,248K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -74,111 | -69,387 | -65,021 | -121,435 |
| Depreciation expense | 408 | 406 | 406 | 606 |
| Equity-based compensation expense | 17,155 | 11,930 | 11,877 | 22,470 |
| Amortization of discounts on marketable securities | 1,549 | 1,742 | 1,620 | 4,139 |
| Non-cash lease expense | 980 | 959 | 940 | 1,778 |
| Prepaid expenses and other current assets | 2,490 | -1,642 | 2,106 | 1,642 |
| Other non-current assets | -155 | -73 | 181 | 8,359 |
| Accounts payable | 16 | 845 | -5,302 | 4,607 |
| Operating lease liability | -802 | -1,004 | -992 | -1,985 |
| Accrued expenses | 4,668 | -6,411 | 7,744 | -2,407 |
| Purchases of property and equipment | - | 62 | 0 | 5,085 |
| Net cash used in operating activities | -55,570 | -62,689 | -54,255 | -110,506 |
| Purchases of marketable securities | 183,244 | 389,088 | 107,632 | 145,580 |
| Maturities of marketable securities | 147,895 | 100,524 | 125,577 | 241,772 |
| Net cash (used in) provided by investing activities | -35,349 | -288,626 | 17,945 | 91,107 |
| Proceeds from issuance of common stock, net of issuance costs | 378,169 | - | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | - | 324,052 | - | - |
| Proceeds from issuance of common stock under the atm facility, net of issuance costs | 9,552 | - | 19,382 | - |
| Proceeds from issuance of common stock under atm equity offering program, net of issuance costs | - | 65,582 | - | - |
| Proceeds from exercise of options and employee stock purchase plan purchases | - | 4,698 | 356 | 1,802 |
| Proceeds from exercise of options | 4,064 | - | - | - |
| Net cash provided by financing activities | 411,167 | 374,950 | 19,738 | 1,802 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 320,248 | 23,635 | -16,572 | -17,597 |
| Cash, cash equivalents and restricted cash, beginning of period | 131,549 | 107,914 | 142,083 | - |
| Cash, cash equivalents and restricted cash, end of period | 451,797 | 131,549 | 107,914 | - |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)